2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Pathology, Serologic Tests, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Apoptosis, Pathogenesis, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, GVHD, Neutropenia, Infectious Diseases, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

5855 A brief pulse of interleukin-6, such as occurs following brain death, enhances fitness of primitive bone marrow hematopoietic stem cells for transplantation

Brian H. Johnstone, PhD, Jie Jiang, PhD2, Dongsheng Gu, PhD3, Ding-Wen Chen, PhD4, Sagar Munjal, MD, MS5, Richi Man Chugh, PhD6, Subhrajit Saha, PhD7, Erik J Woods, PhD8
1 Ossium Health, Inc., Indianapolis, Indiana, United States
2 Ossium Health, Inc., Indianapolis, Indiana, United States
3 Ossium Health, Inc., Indianapolis, Indiana, United States
4 Ossium Health, Inc., Indianapolis, Indiana, United States
5 Ossium Health, San Francisco, California, United States
6 University of Kansas Medical Center, Kansas City, Kansas, United States
7 University of Kansas Medical Center, Kansas City, Kansas, United States
8 Ossium Health, Inc., Indianapolis, Indiana, United States

Allogeneic hematopoietic cell transplantation (alloHCT) is a curative treatment for many bone marrow (BM) disorders; however, the current transplant system that heavily relies on living donor volunteers is beset with operational inefficiencies. Consequently, a significant number of patients requiring alloHCT are not served because donor grafts cannot be procured within the required therapeutic window. A current initiative to build a genetically diverse bank of cryopreserved whole BM recovered from consented and screened deceased organ donor (OD) vertebral bodies (VBs) addresses the need for on-demand grafts with validated functionally viable CD34+ and accessory cells. Early clinical trial data using this novel graft source for alloHCT to treat malignancies have demonstrated remarkable outcomes with highly mismatched grafts (4-6/8) and post-transplant cyclophosphamide (PTCy) GVHD prophylaxis (abstracts submitted). The present study investigated whether pathophysiological processes associated with brain death alter hematopoietic stem cell (HSC) fitness for alloHCT.

As previously demonstrated, a temporally restricted wave of IL-6 occurs with brain death. IL-6 levels in brain dead donor (BDD) VB BM inversely correlated with the interval between declaration of brain death and recovery of VBs (Spearman rs =−0.603, P=0.0049). The average concentration of IL-6 in BDD BM (N=9) was 206.5 ± 359.2 pg/mL, compared to 55.22 ± 100.8 pg/mL in plasma. The level of IL-6 in BDD BM is >100-fold greater than what has been reported in healthy donor (HD) BM (1.7 pg/ml). scRNA-seq analysis revealed an enhanced IL-6-mediated JAK/STAT3 signaling imprint on BDD BM HSCs, enhancing resilience of primitive long-term repopulating HSCs (LT-HSCs).

The transient IL-6 wave phenomenon was modeled in vitro by subjecting living healthy donor (HD) BM CD34+ cells to a brief (40 h) IL-6 stimulation at low levels (1 ng/ml), with and without soluble IL-6 receptor (sIL-6R) and then incubated for 5 days in minimal medium with SCF, TPO and FLT3L (STF). LT-HSCs lack membrane IL-6R but can signal in trans through binding of IL-6/sIL-6R complexes to the membrane gp130 protein receptor binding partner. The proportion of LT-HSCs doubled (P<0.05, ANOVA) after IL-6 stimulation in combination with sIL-6R compared to controls. Enhanced LT-HSC numbers were associated with greater viability and proliferation (CFSE dilution), resulting in 2±0.59-fold cell numbers (P<0.05, ANOVA). Pulsing with IL-6/sIL-6R also increased the clonogenic capacity of CD34+ cells without evidence of myeloid skewing as determined by colony forming unit (CFU) assays. In contrast, supraphysiological concentrations (10 and 100 ng/mL) commonly used in vitro strongly skewed towards CFU-GM (P<0.05).

We next evaluated whether an IL-6/sIL-6R pulse conferred a survival advantage upon LT-HSCs cultured under stress conditions. HD CD34+ cells were pulsed with IL-6/sIL-6R for 40 h in serum-free medium without STF cytokines. Cell numbers in the LT-HSC compartment were over 3-fold greater than control (P<0.01, ANOVA) when pulsed with IL-6/sIL-6R, which was abrogated by neutralization with sgp130Fc inhibitor. Increased survival was due to reduced cell death (27.6%) compared to the untreated controls (76.4%). Real-time PCR analysis revealed that an IL-6/sIL-6R pulse upregulated expression of stress response and growth genes such as MCL1 (1.4-fold) and JUNB (1.5-fold), conferring enhanced resilience in stress conditions. A similar enhancement of IL-6/sIL-6R pulsed LT-HSC survival was observed with an inflammatory challenge using a cocktail of factors similar to that found post-conditioning, consisting of interferon-γ, tumor necrosis factor α and interleukin1β. Importantly, stimulation of feedback regulatory mechanisms, such as SOCS1/3 (1.5 and 4.3-fold, respectively, over control), was observed which serves to limit inflammatory processes. Thus, together with PIM1 (4.8-fold increased) and BCL3 (3.1-fold increased), factors induced by a low dose IL-6/sIL-6R pulse appear to preserve LT-HSCs by preventing myeloid skewing and exhaustion, which were both observed with supraphysiological IL-6 concentrations commonly used to evaluate signaling in HSCs.

These data provide a potential mechanistic bridge between deceased donor inflammatory conditions that enhance resilience of LT-HSCs, leading to rapid engraftment and early indices of low relapse in clinical studies using BD donor BM for alloHCT (NCT05589896 and NCT07145411).

Brian H. Johnstone, PhD: Ossium Health, Inc. - Current holder of stock options in a privately-held company; Ossium Health, Inc. - Current Employment